Thyrotropin Receptor Antibodies
TRAB
Description
"Peripheral Antineutrophil Cytoplasmic Antibodies" (p-ANCA) test identifies antibodies linked to autoimmune diseases such as microscopic polyangiitis or ulcerative colitis. It’s typically ordered when patients experience fatigue, joint pain, or unexplained organ inflammation. High p-ANCA levels point to immune-related blood vessel inflammation and systemic autoimmune activity. Results help doctors confirm a diagnosis and start appropriate treatment, often involving immunosuppressants or further testing. Tracking antibody levels supports long-term management and helps prevent complications from untreated or progressive autoimmune conditions.
Category
Autoantibodies, Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
International Units Per Liter
Procedure Category
Blood Draw
Test Group
Complete Thyroid Group, Autoimmune Condition Group
Test Group Description
Complete Thyroid Group: A comprehensive array of tests for a thorough evaluation of thyroid function, providing detailed insights into thyroid health and associated conditions. Autoimmune Condition Group: Tests within this group focus on markers associated with autoimmune diseases, providing insights into the body's immune response against its own tissues.
Optimal Range
For All Individuals:
Conventional Unit: <0.55 IU/L
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 0.00–1.75 IU/L
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Graves' disease (Autoimmune hyperthyroidism)
Hashitoxicosis (Thyroid inflammation causing hyperthyroidism)
Neonatal Graves' disease (Hyperthyroidism in newborns)
Postpartum thyroiditis (Thyroid inflammation after childbirth)
Toxic nodular goiter (Enlarged thyroid with overactive nodules)
Key Reasons For Testing
Graves' Disease Diagnosis: Essential for confirming Graves' disease, the leading cause of hyperthyroidism.
Differentiation of Thyroid Disorders: Helps distinguish Graves' disease from Hashimoto’s or toxic goiter.
Monitoring Response to Treatment: Tracks therapy efficacy and guides adjustments in Graves' disease.
Predictive Marker for Graves' Ophthalmopathy: Indicates risk and severity of this complication, aiding early intervention.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Morshed SA, Davies TF. Thyrotropin receptor antibodies and their role in the hyperthyroidism of Graves’ disease. Front Biosci. 2012;4(1):2072-2084.
[2] Struja T, Jutzi R, Imahorn N, et al. Comparison of five TSH-receptor antibody assays in Graves’ disease: results from an observational pilot study. BMC Endocr Disord. 2019;19(1):38.
[3] Diana T, Kanitz M, Lehmann M, et al. Standardization of a bioassay for thyrotropin receptor antibodies: the first WHO international standard. Eur Thyroid J. 2018;7(4):292-299.
[4] Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98(6):2247-2255.
[5] Kahaly GJ, Diana T, Glang J, et al. Thyroid stimulating antibodies are highly prevalent in Hashimoto's thyroiditis and associated orbitopathy. J Clin Endocrinol Metab. 2016;101(5):1998-2004.
[6] Kamijo K. TSH receptor antibodies in Graves’ disease: functional activities and clinical applications. Endocr J. 2000;47(4):471-482.
[7] Massart C, Orgiazzi J, Maugendre D. Clinical value of the combined determination of thyrotropin receptor and thyroperoxidase antibodies in the diagnosis of autoimmune thyroid diseases. Eur J Endocrinol. 1997;136(1):81-86.
[8] McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinol Metab Clin North Am. 1998;27(1):73-89.
[9] Diana T, Olivo PD, Kahaly GJ. Thyrotropin receptor blocking antibodies. Horm Metab Res. 2018;50(12):853-862.
[10] Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016;375(16):1552-1565.
[11] Wiersinga WM. Clinical relevance of TSH receptor autoantibodies. J Endocrinol Invest. 1995;18(5):381-383.
[12] Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008;358(24):2594-2605.
[13] Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69-75.